Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (17)

Pneumonia (7)

Anosmia (7)

Cough (6)

Falls (5)


Transmission

Seroprevalence
    displaying 21 - 30 records in total 381
    records per page




    Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach

    Authors: Christos F Fotis; Nikolaos Meimetis; Nikos Tsolakos; Marianna Politou; Karolina Akinosoglou; Vicky Pliaka; Angeliki Minia; Evangelos Terpos; Ioannis P. Trougakos; Andreas Mentis; Markos Marangos; George Panayiotakopoulos; Meletios A. Dimopoulos; Charalampos Gogos; Alexandros Spyridonidis; Leonidas G. Alexopoulos

    doi:10.1101/2020.09.09.20191122 Date: 2020-09-10 Source: medRxiv

    More than 300 SARS-COV-2 serological tests SERO have recently been developed using either the nucleocapsid phosphoprotein (N), the spike glycoprotein subunit (S1), and more recently the receptor binding domain (RBD). Most of the assays report very good clinical performance SERO characteristics in well-controlled clinical settings. However, there is a growing belief that good performance SERO characteristics that are obtained during clinical performance SERO trials might not be sufficient to deliver good diagnostic results in population-wide screens that are usually characterized with low seroprevalence SERO. In this paper, we developed a serological assay SERO against N, S1 and RBD using a bead-based multiplex platform and a rules-based computational approach to assess the performance SERO of single and multi-antigen readouts in well-defined clinical samples and in a population-wide serosurvey from blood SERO donors. Even though assays based on single antigen readouts performed similarly well in the clinical samples, there was a striking difference between the antigens on the population-wide screen. Asymptomatic TRANS individuals with low antibody SERO titers and sub-optimal assay specificity might contribute to the large discrepancies in population studies with low seroprevalence SERO. A multi-antigen assay requiring partial agreement between RBD, N and S1 readouts exhibited enhanced specificity, less dependency on assay cut-off values and an overall more robust performance SERO in both sample settings. Our data suggest that assays based on multiple antigen readouts combined with a rules-based computational consensus can provide a more robust platform for routine antibody SERO screening.

    Inference of SARS-CoV-2 spike-binding neutralizing antibody SERO titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays SERO

    Authors: Arantxa Valdivia; Ignacio Torres; Victor Latorre; Carla Frances-Gomez; Eliseo Albert; Roberto Gozalbo; Maria Jesus Alcaraz; Javier Buesa; Jesus Rodriguez-Diaz; Ron Geller; David Navarro; Maria Gabrani; Michal Rosen-Zvi

    doi:10.1101/2020.09.07.20188151 Date: 2020-09-09 Source: medRxiv

    Background: Whether antibody SERO levels measured by commercially-available enzyme or chemiluminescent immunoassays SERO targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum SERO neutralizing activity remains to be established for many of these assays. Objectives: To evaluate the degree of correlation between neutralizing antibodies SERO (NtAb) binding the SARS-CoV-2 Spike MESHD (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays SERO in sera drawn from hospitalized COVID-19 patients. Patients and Methods: Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA SERO, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG SERO assays. Results: Overall, the results obtained with the COVID-19 ELISA IgG SERO test showed the highest agreement with the NtAb assay ({kappa}, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG SERO assay (92.2% for both). Overall, the degree correlation between antibody SERO titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA SERO (Rho=0.73) and moderate for the remaining assays (Rho=0.48 to 0.59). The kinetic profile of serum SERO NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays SERO. Conclusions: the suitability of SARS-CoV-2-S-IgG commercial immunoassays SERO for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms TRANS.

    Comparative evaluation of six immunoassays SERO for the detection of antibodies SERO against SARS-CoV-2

    Authors: Felipe Perez-Garcia; Ramon Perez-Tanoira; Maria Esther Iglesias; Juan Romanyk; Teresa Arroyo; Pena Gomez-Herruz; Rosa Gonzalez; Juan Cuadros-Gonzalez; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre; Sacha Gnjatic; Noam Harpaz; Silvio Danese; Adeeb Rahman; Nikhil A Kumta; Alessio Aghemo; Francesca Petralia; Harm van Bakel; Adolfo Garcia-Sastre; Saurabh Mehandru

    doi:10.1101/2020.09.08.20190488 Date: 2020-09-09 Source: medRxiv

    Objectives: Serologic techniques can serve as a complement to diagnose SARS-CoV-2 infection MESHD. The objective of our study was to compare the diagnostic performance SERO of six immunoassays SERO to detect antibodies SERO against SARS-CoV-2: three lateral flow immunoassays SERO (LFAs), one ELISA SERO and two chemiluminescence assays (CLIAs). Methods: We evaluated three LFAs (Alltest, One Step and SeroFlash), one ELISA SERO (Dia.Pro) and two CLIAs (Elecsys and COV2T). To assess the specificity, 60 pre-pandemic sera were used. To evaluate the sensitivity SERO, we used 80 serum samples SERO from patients with positive PCR for SARS-CoV-2. Agreement between techniques was evaluated using the kappa score (k). Results: All immunoassays SERO showed a specificity of 100% except for SeroFlash (96.7%). Overall sensitivity SERO was 61.3%, 73.8%, 67.5%, 85.9%, 88.0% and 92.0% for Alltest, One Step, SeroFlash, Dia.Pro, Elecsys and COV2T, respectively. Sensitivity SERO increased throughout the first two weeks from the onset of symptoms TRANS, reaching sensitivities SERO over 85% from 14 days for all LFAs, being One Step the most sensitive (97.6%), followed by SeroFlash (95.1%). Dia.Pro, Elecsys and COV2T showed sensitivities SERO over 97% from 14 days, being 100% for COV2T. One Step showed the best agreement results among LFAs, showing excellent agreement with Dia.Pro (agreement=94.2%, k=0.884), COV2T (99.1%, k=0.981) and Elecsys (97.3%, k=0.943). Dia.Pro, COV2T and Elecsys also showed excellent agreement between them. Conclusions: One Step, Dia.Pro, Elecsys and COV2T obtained the best diagnostic performance SERO results. All these techniques showed a specificity of 100% and sensitivities SERO over 97% from 14 days after the onset of symptoms TRANS, as well as excellent levels of agreement.

    Antibody SERO binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization

    Authors: Shilei Ding; Annemarie Laumaea; Romain Gasser; Halima Medjahed; Marie Pancera; Leonidas Stamatatos; Andrew McGuire; Renee Bazin; Andres Finzi; Alptekin Gueler; Jakob Loschko; Mohan Maddur; Kristin Tompkins; Journey Cole; Bonny Gaby Lui; Thomas Ziegenhals; Arianne Plaschke; David Eisel; Sarah Dany; Stephanie Fesser; Stephanie Erbar; ferdia Bates; Diana Schneider; Bernadette Jesionek; Bianca Saenger; Ann-Kathrin Wallisch; Yvonne Feuchter; Hanna Junginger; Stefanie Krumm; Andre Heinen; Petra Adams-Quack; Julia Schlereth; Christoph Kroener; Shannan Hall-Ursone; Kathleen Brasky; Matthew C Griffor; Seungil Han; Joshua Lees; Ellene Mashalidis; Parag Sahasrabudhe; Charles Tan; Danka Pavliakova; Guy Singh; Camila Fontes-Garfias; Michael Pride; Ingrid Scully; tara Ciolino; Jennifer Obregon; Michal Gazi; Ricardo Carrion; Kendra Alfson; Warren Kalina; Deepak Kaushal; Pei-Yong Shi; Thorsten Klamp; Corinna Rosenbaum; Andreas Kuhn; Oezlem Tuereci; Philip Dormitzer; Kathrin Jansen; Ugur Sahin; Akhilesh Kumar Maurya; K Hemanth; K Nagamani; K Sudha; T Ravi Chandra; K Tushara Rao; J Vyshnavi; Rashmi Upadhyay; Shalini Bahadur; Rambha Pathak; Shikha Seth; Rakesh Gupta; Rita Saxena; Preksha Dwivedi; Reeni Malik; Deepti Chourasia; Jaya Lalwani; UM Sharma; JL Marko; Amit Suri; Vijay Kumar; Rajnish Kaushik; Parul Kodan; Bhabani Prasad Acharya; Kuldeep Kumar Gaur; Anubhav Gupta; Prerna Sachdeva; Shruti Dogra; Aikaj Jindal; M Joseph John; Avtar Singh Dhanju; Ranjana Khetrepal; Neeraj Sharma; Neetu Kukar; Divya Kavita; Rajesh Kumar; Rajesh Mahajan; Gurpreet Singh; Jaspreet Kaur; Raminder Pal Singh; Rajni Bassi; Swapneil Parikh; Om Shrivastav; Jayanthi Shastri; Maherra Desai; Shreevatsa Udupa; Varun A Bafna; Vijay Barge; Rajendra Madane; Sheetal Yadav; Sanjeev Mishra; Archana Bajpayee; M K Garg; G K Bohra; Vijaylakshmi Nag; Puneeth Babu Anne; Mohd Nadeem; Pallavi Singh; Ram Niwas; Niranjan Shiwaji Khaire; Rattiram Sharma; Mini p Singh; Naresh Sachdeva; Suchet Sachdev; Rekha Hans; Vikas Suri; L N Yaddanapudi; PVM Lakshmi; Neha Singh; Divendu Bhushan; Neeraj Kumar; Muralidhar Tambe; Sonali Salvi; Nalini Kadgi; Shashikala Sangle; Leena Nakate; Samir Joshi; Rajesh Karyakarte; Suraj Goyanka; Nimisha Sharma; Nikhil Verma; Asim Das; Monika Bahl; Nitya Wadhwa; Shreepad Bhat; Shweta Deshmukh; Vrushali Wagh; Atul Kulkarni; Tanvi Yardi; Ram S Kalgud; Purushottam Reddy; Kavitha Yevoor; Prashanth Gajula; Vivek Maleyur; Medini S; Mohith HN; Anil Gurtoo; Ritika Sud; Sangeeta Pahuja; Anupam Prakash; Parijat Gogoi; Shailja Shukla; D Himanshu Reddy; Tulika Chandra; Saurabh Pandey; Pradeep Maurya; Ali Wahid; Vivek Kumar; Kamlesh Upadhyay; Nidhi Bhatnagar; Nilima Shah; Mamta Shah; Tarak Patel; Ram Mohan Jaiswal; Ashish Jain; Shweta Sharma; Puneet Rijhwani; Naveen Gupta; Tinkal C Patel; Mahesh G Solu; Jitendra Patel; Yash R Shah; Mayur Jarag; Varsha Godbole; Meenakshi Shah; Rikin Raj; Irfan Nagori; Pramod R Jha; Arti D Shah; Gowtham Yeeli; Archit Jain; Rooppreet Kaur Gill; KV Sreedhar Babu; B Suresh Babu; Alladi Mohan; B Vengamma; K Chandra Sekhar; Srinivasulu Damam; K Narsimhulu; C Aparna; G Baleswari; Ravindranath Reddy K; P Chandrasekhar; Sunil Jodharam Panjwani; Pankaj J Akholkar; Kairavi Parthesh Joshi; Pragnesh H Shah; Manish Barvaliya; Milind Baldi; Ashok Yadav; Manoj Gupta; Nitin Rawat; Dilip Chawda; M Natarajan; M Sintha; David Pradeep Kumar; Fathhur Rabbani; Vrushali Khirid Khadke; Dattatray Patki; Sonali Marathe; Clyde D Souza; Vipul Tadha; Satyam Arora; Devendra Kumar Gupta; Seema Dua; Nitu Chauhan; Ajeet Singh Chahar; Joy John Mammen; Snehil Kumar; Dolly Daniel; Ravindraa Singh; Venkatesh Dhat; Yogesh Agarwal; Sohini Arora; Ashish Pathak; Manju Purohit; Ashish Sharma; Jayashree Sharma; Manisha Madkaikar; Kavita Joshi; Reetika Malik Yadav; Swarupa Bhagwat; Niteen D Karnik; Yojana A Gokhale; Leena Naik; Sangita Margam; Santasabuj Das; Alka Turuk; V Saravana Kumar; K Kanagasabai; R Sabarinathan; Gururaj Deshpande; Sharda Sharma; Rashmi Gunjikar; Anita Shete; Darpan Phagiwala; Chetan Patil; Snehal Shingade; Kajal Jarande; Himanshu Kaushal; Pragya Yadav; Gajanan Sapkal; Priya Abraham

    doi:10.1101/2020.09.08.287482 Date: 2020-09-08 Source: bioRxiv

    Convalescent plasma SERO from SARS-CoV-2 infected MESHD individuals and monoclonal antibodies SERO were shown to potently neutralize viral and pseudoviral particles carrying the S glycoprotein. However, a non-negligent proportion of plasma SERO samples from infected individuals as well as S-specific monoclonal antibodies SERO were reported to be non-neutralizing despite efficient interaction with the S glycoprotein in different biochemical assays using soluble recombinant forms of S or when expressed at the cell surface. How neutralization relates to binding of S glycoprotein in the context of viral particles remains to be established. Here we developed a pseudovirus capture assay (VCA) to measure the capacity of plasma SERO samples or antibodies SERO immobilized on ELISA SERO plates to bind to membrane-bound S glycoproteins from SARS-CoV-2 expressed at the surface of lentiviral particles. By performing VCA and neutralization assays we observed a strong correlation between these two parameters. However, while we found that plasma SERO samples unable to capture viral particles did not neutralize, capture did not guarantee neutralization, indicating that the capacity of antibodies SERO to bind to the S glycoprotein at the surface of viral particles is required but not sufficient to mediate neutralization. Altogether, our results highlights the importance of better understanding the inactivation of S by plasma SERO and neutralizing antibodies SERO.

    Antibody SERO Responses to SARS-CoV-2 in Coronavirus Diseases MESHD 2019 Patients with Different Severity

    Authors: Ekasit Kowitdamrong; Thanyawee Puthanakit; Watsamon Jantarabenjakul; Eakachai Prompetchara; Pintip Suchartlikitwong; Opass Putcharoen; Nattiya Hirankarn; Ke Lan; Yu Chen; Huabin Zhao

    doi:10.1101/2020.09.06.20189480 Date: 2020-09-08 Source: medRxiv

    Background: More understanding of antibody SERO responses in the SARS-CoV-2 infected MESHD population is useful for vaccine development. Aim: To investigate SARS-CoV-2 IgA MESHD and IgG among COVID-19 Thai patients with different severity. Methods: We used plasma SERO from 118 adult TRANS patients who have confirmed SARS-CoV-2 infection MESHD and 49 patients under investigation without infection MESHD, 20 patients with other respiratory infections MESHD, and 102 healthy controls. Anti-SARS-CoV-2 IgA and IgG were performed by enzyme-linked immunosorbent assay SERO from Euroimmun. The optical density ratio cut off for positive test was 1.1 for IgA and 0.8 for IgG. The association of antibody SERO response with the severity of diseases and the day of symptoms was performed. Results: From Mar 10 to May 31, 2020, 289 participants were enrolled, and 384 samples were analyzed. Patients were categorized by clinical manifestations to mild (n=59), moderate (n=27) and severe (n=32). The overall sensitivity SERO of IgA and IgG from samples collected after day 7 is 87.9% (95% CI 79.8-93.6) and 84.8% (95% CI 76.2-91.3), respectively. The severe group had a significantly higher level of specific IgA and IgG to S1 antigen compared to the mild group. All moderate to severe patients have specific IgG while 20% of the mild group did not have any IgG detected after two weeks. Interestingly, SARS-CoV-2 IgG level was significantly higher in males TRANS compared to females TRANS among the severe group (p=0.003). Conclusion: The serologic test SERO for SARS-CoV-2 has high sensitivity SERO after the second week after onset of illness. Serological response differs among patients with different severity and different sex.

    Clinical Performance SERO Evaluation of a SARS-CoV-2 Rapid Antibody Test SERO for Determining Past Exposure to SARS-CoV-2

    Authors: Peter Findeisen; Hugo Stiegler; Eloisa Lopez-Calle; Tanja Schneider; Eva Urlaub; Johannes Hayer; Claudia Silke Zemmrich

    doi:10.1101/2020.09.01.20180687 Date: 2020-09-04 Source: medRxiv

    The true prevalence SERO and population seropositivity of SARS-CoV-2 infection MESHD remains unknown, due to the number of asymptomatic TRANS infections MESHD and limited access to high- performance SERO antibody tests SERO. To control the COVID-19 pandemic it is crucial to understand the true seroprevalence SERO, but not every region has access to extensive centralized PCR and serology testing. Currently available rapid antibody tests SERO lack the accuracy needed for recommendation by health authorities. To fill this gap, we analyzed and validated the clinical performance SERO of a new point-of-care SARS-CoV-2 Rapid Antibody SERO Assay, a chromatographic immunoassay SERO for qualitative detection of IgM/IgG antibodies SERO for use in near-patient settings. Analysis was performed using 42 Anti-SARS-Cov-2 positive (CoV+) and 92 Anti-SARS-Covid-2 negative (CoV-) leftover samples from before December 2019, using the Elecsys(R) Anti-SARS-CoV-2 as the reference assay. Analytical specificity was tested using leftover samples from individuals with symptoms of common cold collected before December 2019. The SARS-CoV-2 Rapid Antibody Test SERO was 100.0% (95% CI 91.59-100.00) sensitive and 96.74% (95% CI 90.77-99.32) specific with an assay failure rate of 0.00%. No cross-reactivity was observed against the common cold panel. Method comparison was additionally conducted by two external laboratories, using 100 CoV+/275 CoV- samples, also comparing whole blood SERO versus plasma SERO matrix. The comparison demonstrated for plasma SERO 96.00% positive/96.36% negative percent agreement with the Elecsys Anti-SARS-CoV-2 and overall 99.20% percent agreement between whole blood SERO and EDTA plasma SERO. The SARS-CoV-2 Rapid Antibody Test SERO demonstrated similar clinical performance SERO to the manufacturer's data and to a centralized automated immunoassay SERO, with no cross-reactivity to common cold panels.

    Seroprevalence SERO of SARS-CoV-2 specific IgG antibodies SERO in District Srinagar, northern India - a cross-sectional study

    Authors: S Muhammad Salim Khan; Mariya Amin Qurieshi; Inaamul Haq; Sabhiya Majid; Arif Akbar Bhat; Sahila Nabi; Nisar Ahmad Ganai; Nazia Zahoor; Auqfeen Nisar; Iqra Nisar Chowdri; Tanzeela Bashir Qazi; Rafiya Kousar; Abdul Aziz Lone; Iram Sabah; Shahroz Nabi; Ishtiyaq Ahmad Sumji; Misbah Ferooz Kawoosa; Shifana Ayoub; Ozden Hatirnaz Ng; Sezer Akyoney; Ilayda Sahin; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Ercument Ovali

    doi:10.1101/2020.09.04.282640 Date: 2020-09-04 Source: bioRxiv

    BackgroundPrevalence of IgG antibodies SERO against SARS-CoV-2 infection MESHD provides essential information for deciding disease prevention and mitigation measures. We estimate the seroprevalence SERO of SARS-CoV-2 specific IgG antibodies SERO in District Srinagar. Methods2906 persons >18 years of age TRANS selected from hospital visitors across District Srinagar participated in the study. We tested samples for the presence of SARS-CoV-2 specific IgG antibodies SERO using a chemiluminescent microparticle immunoassay SERO-based serologic test SERO. ResultsAge- and gender TRANS-standardized seroprevalence SERO was 3.6% (95% CI 2.9% to 4.3%). Age TRANS 30-69 years, a recent history of symptoms of an influenza-like-illness, and a history of being placed under quarantine were significantly related to higher odds of the presence of SARS-CoV-2 specific IgG antibodies SERO. The estimated number of SARS-CoV-2 infections during the two weeks preceding the study, adjusted for test performance SERO, was 32602 with an estimated (median) infection-to-known-case ratio of 46 (95% CI 36 to 57). ConclusionsThe seroprevalence SERO of SARS-CoV-2 specific IgG antibodies SERO is low in the District. A large proportion of the population is still susceptible to the infection. A sizeable number of infections remain undetected, and a substantial proportion of people with symptoms compatible with COVID-19 are not tested.

    Multiplexed, Microscale, Microarray-based Serological Assay SERO for Antibodies SERO Against All Human-Relevant Coronaviruses

    Authors: Erica D Dawson; Laura R Kuck; Rebecca H Blair; Amber W Taylor; Evan Toth; Vijaya Knight; Kathy L Rowlen

    doi:10.1101/2020.09.03.20179598 Date: 2020-09-04 Source: medRxiv

    Rapid, sensitive, and precise multiplexed assays for serological SERO analysis during candidate COVID-19 vaccine development would streamline clinical trials. The VaxArray Coronavirus (CoV) SeroAssay quantifies IgG antibody SERO binding to 9 pandemic, potentially pandemic, and endemic human CoV spike antigens in 2 hours with automated results analysis. IgG antibodies SERO in serum SERO bind to the CoV spike protein capture antigens printed in a microarray format and are labeled with a fluorescent anti-species IgG secondary label. The assay demonstrated excellent lower limits of quantification ranging from 0.3 to 2.0 ng/mL and linear dynamic ranges of 76 to 911-fold. Average precision of 11% CV and accuracy (% recovery) of 92.5% over all capture antigens were achieved over 216 replicates representing 3 days and 3 microarray lots. Clinical performance SERO on 263 human serum samples SERO (132 SARS-CoV-2 negatives and 131 positives based on donor-matched RT-PCR and/or date of collection) produced 98.5% PPA ( sensitivity SERO) and 100% NPA (specificity).

    24 People, one test: Boosting test efficiency using pooled serum SERO antibody testing SERO for SARS-CoV-2

    Authors: Stefan Nessler; Jonas Franz; Franziska van der Meer; Konstantina Kolotourou; Vivek Venkataramani; Chalid Hasan; Beatrix Beatrix Pollok-Kopp; Andreas E Zautner; Christine Stadelmann; Michael Weig; Stefan Poehlmann; Markus Hoffmann; Joachim Riggert; Graham Medley; Michael Hohle; John Edmunds; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Ercument Ovali

    doi:10.1101/2020.09.01.20186130 Date: 2020-09-03 Source: medRxiv

    Background: The global pandemic of COVID-19 (coronavirus disease 2019) is caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2 MESHD), with different prevalence SERO rates across countries and regions. Dynamic testing strategies are mandatory to establish efficient mitigation strategies against the disease; to be cost effective, they should adapt to regional prevalences SERO. Seroprevalence SERO surveys that detect individuals who have mounted an immune response against COVID-19 will help to determine the total number of infections within a community and improve the epidemiological calculations of attack and case fatality rates of the virus. They will also inform about the percentage of a population that might be immune against re-infections. Methods: We developed a sensitive and specific cell-based assay to detect conformational SARS-CoV-2 spike MESHD (SARS-2-S) S1 antibodies SERO in human serum SERO, and have cross-evaluated this assay against two FDA-approved SARS-CoV-2 antibody SERO assays. We performed pseudovirus neutralization assays to determine whether sera that were rated antibody SERO-positive in our assay were able to specifically neutralize SARS-2-S. We pooled up to 24 sera and assessed the group testing performance SERO of our cell-based assay. Group testing was further optimized by Monte Carlo like simulations and prospectively evaluated. Findings: Highly significant correlations could be established between our cell-based assay and commercial antibody tests SERO for SARS-CoV-2. SARS-2-S S1 antibody SERO-positive sera neutralized SARS-2-S but not SARS-S MESHD, and were sensitively and specifically detected in pools of 24 samples. Monte Carlo like simulations demonstrated that a simple two-step pooling scheme with fixed pool sizes performed at least equally as well as Dorfman's optimal testing across a wide range of antibody SERO prevalences SERO. Interpretation: We demonstrate that a cell-based assay for SARS-2-S S1 antibodies SERO qualifies for group testing of neutralizing anti-SARS-2-S antibodies SERO. The assay can be combined with an easily implemented algorithm which greatly expands the screening capacity to detect anti-SARS-2-S antibodies SERO across a wide range of antibody SERO prevalences SERO. It will thus improve population serological testing SERO in many countries.

    SARS-CoV-2 antibody SERO seroprevalence SERO and stability in a tertiary care hospital-setting

    Authors: Samreen Siddiqui; Salwa Naushin; Shalini Pradhan; Archa Misra; Akansha Tyagi; Menka Loomba; Swati Waghdhare; Rajesh Pandey; Shantanu Sengupta; Sujeet Jha; Edward Burn; Paula Casajust; Dalia Dawoud; Scott L DuVall; Thomas Falconer; Sergio Fernandez-Bertolin; Asieh Golozar; Mengchun Gong; Lana Yin Hui Lai; Jennifer C.E Lane; Kristine E Lynch; Michael E Matheny; Paras P Mehta; Daniel R Morales; Karthik Natarjan; Fredrik Nyberg; Jose D Posada; Christian G Reich; Lisa M Schilling; Karishma Shah; Nigham H Shah; Vignesh Subbian; Lin Zhang; Hong Zhu; Patrick Ryan; Daniel Prieto-Alhambra; Kristin Kostka; Talita Duarte-Salles

    doi:10.1101/2020.09.02.20186486 Date: 2020-09-03 Source: medRxiv

    Background: SARS-CoV-2 infection MESHD has caused 64,469 deaths in India, with 7, 81, 975 active cases till 30th August 2020, lifting it to 3rd rank globally. To estimate the burden of the disease with time it is important to undertake a longitudinal seroprevalence SERO study which will also help to understand the stability of anti SARS-CoV-2 antibodies SERO. Various studies have been conducted worldwide to assess the antibody SERO stability. However, there is very limited data available from India. Healthcare workers (HCW) are the frontline workforce and more exposed to the COVID-19 infection (SARS-CoV-2) compared to the community. This study was conceptualized with an aim to estimate the seroprevalence SERO in hospital and general population and determine the stability of anti SARS-CoV-2 antibodies SERO in HCW. Methods: Staff of a tertiary care hospital in Delhi and individuals visiting that hospital were recruited between April to August 2020. Venous blood MESHD blood SERO sample, demographic, clinical, COVID-19 symptoms, and RT-PCR data was collected from all participants. Serological testing SERO was performed using the electro-chemiluminescence based assay developed by Roche Diagnostics, in Cobas Elecsys 411. Seropositive participants were followed- upto 83 days to check for the presence of antibodies SERO. Results: A total of 780 participants were included in this study, which comprised 448 HCW and 332 individuals from the general population. Among the HCW, seroprevalence SERO rates increased from 2.3% in April to 50.6% in July. The cumulative prevalence SERO was 16.5% in HCW and 23.5% (78/332) in the general population with a large number of asymptomatic TRANS individuals. Out of 74 seropositive HCWs, 51 were followed-up for the duration of this study. We observed that in all seropositive cases the antibodies SERO were sustained even up to 83 days. Conclusion: The cumulative prevalence SERO of seropositivity was lower in HCWs than the general population. There were a large number of asymptomatic TRANS cases and the antibodies SERO developed persisted through the duration of the study. More such longitudinal serology studies are needed to better understand the antibody SERO response kinetics.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.